Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis.
COVID-19
ESRD
SARS-CoV-2
chronic kidney failure
dialysis
end-stage renal disease
infectiousness
infectivity
outpatients
Journal
Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381
Informations de publication
Date de publication:
30 12 2021
30 12 2021
Historique:
received:
01
07
2021
accepted:
14
09
2021
entrez:
14
4
2022
pubmed:
15
4
2022
medline:
16
4
2022
Statut:
epublish
Résumé
Patients with ESKD on maintenance dialysis receive dialysis in common spaces with other patients and have a higher risk of severe SARS-CoV-2 infections. They may have persistently or intermittently positive SARS-CoV-2 RT-PCR tests after infection. We describe the clinical course of SARS-CoV-2 infection and the serologic response in a convenience sample of patients with ESKD to understand the duration of infectivity. From August to November 2020, we enrolled patients on maintenance dialysis with SARS-CoV-2 infections from outpatient dialysis facilities in Atlanta, Georgia. We followed participants for approximately 42 days. We assessed COVID-19 symptoms and collected specimens. Oropharyngeal (OP), anterior nasal (AN), and saliva (SA) specimens were tested for the presence of SARS-CoV-2 RNA, using RT-PCR, and sent for viral culture. Serology, including neutralizing antibodies, was measured in blood specimens. Fifteen participants, with a median age of 58 (range, 37‒77) years, were enrolled. Median duration of RT-PCR positivity from diagnosis was 18 days (interquartile range [IQR], 8‒24 days). Ten participants had at least one, for a total of 41, positive RT-PCR specimens ≥10 days after symptoms onset. Of these 41 specimens, 21 underwent viral culture; one (5%) was positive 14 days after symptom onset. Thirteen participants developed SARS-CoV-2-specific antibodies, 11 of which included neutralizing antibodies. RT-PCRs remained positive after seroconversion in eight participants and after detection of neutralizing antibodies in four participants; however, all of these samples were culture negative. Patients with ESKD on maintenance dialysis remained persistently and intermittently SARS-CoV-2-RT-PCR positive. However, of the 15 participants, only one had infectious virus, on day 14 after symptom onset. Most participants mounted an antibody response, including neutralizing antibodies. Participants continued having RT-PCR-positive results in the presence of SARS-CoV-2-specific antibodies, but without replication-competent virus detected.
Sections du résumé
Background
Patients with ESKD on maintenance dialysis receive dialysis in common spaces with other patients and have a higher risk of severe SARS-CoV-2 infections. They may have persistently or intermittently positive SARS-CoV-2 RT-PCR tests after infection. We describe the clinical course of SARS-CoV-2 infection and the serologic response in a convenience sample of patients with ESKD to understand the duration of infectivity.
Methods
From August to November 2020, we enrolled patients on maintenance dialysis with SARS-CoV-2 infections from outpatient dialysis facilities in Atlanta, Georgia. We followed participants for approximately 42 days. We assessed COVID-19 symptoms and collected specimens. Oropharyngeal (OP), anterior nasal (AN), and saliva (SA) specimens were tested for the presence of SARS-CoV-2 RNA, using RT-PCR, and sent for viral culture. Serology, including neutralizing antibodies, was measured in blood specimens.
Results
Fifteen participants, with a median age of 58 (range, 37‒77) years, were enrolled. Median duration of RT-PCR positivity from diagnosis was 18 days (interquartile range [IQR], 8‒24 days). Ten participants had at least one, for a total of 41, positive RT-PCR specimens ≥10 days after symptoms onset. Of these 41 specimens, 21 underwent viral culture; one (5%) was positive 14 days after symptom onset. Thirteen participants developed SARS-CoV-2-specific antibodies, 11 of which included neutralizing antibodies. RT-PCRs remained positive after seroconversion in eight participants and after detection of neutralizing antibodies in four participants; however, all of these samples were culture negative.
Conclusions
Patients with ESKD on maintenance dialysis remained persistently and intermittently SARS-CoV-2-RT-PCR positive. However, of the 15 participants, only one had infectious virus, on day 14 after symptom onset. Most participants mounted an antibody response, including neutralizing antibodies. Participants continued having RT-PCR-positive results in the presence of SARS-CoV-2-specific antibodies, but without replication-competent virus detected.
Identifiants
pubmed: 35419540
doi: 10.34067/KID.0004372021
pii: 02200512-202112000-00009
pmc: PMC8986054
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1917-1927Informations de copyright
Copyright © 2021 by the American Society of Nephrology.
Déclaration de conflit d'intérêts
I. Apata reports having consultancy agreements with the CDC. L. S. Dalrymple reports having ownership interest in Fresenius Medical Care (via share options) and owning stock in GE; serving as a member of the Kidney Care Quality Alliance Steering Committee, cochair of the Kidney Health Initiative (KHI) ESRD Global Data Standard Workgroup, and cochair of the National Quality Forum Renal Standing Committee; and serving on the Kidney Medicine editorial board. L. S. Dalrymple also reports her husband owned stock in Bayer, CVS, and GE in the last 36 months, and has shares in The Permanente Medical Group. P. R. Patel reports having other interests in/relationships with American Association of Kidney Patients. R. L. Wingard reports having ownership interest in Fresenius Medical Care North America (via stock options), serving as a member of the KHI Muscle Cramping PRO Project, and serving as a volunteer for Welcome Home of Chattanooga (a nonprofit). All remaining authors have nothing to disclose.
Références
Am J Kidney Dis. 2020 Oct;76(4):598
pubmed: 32603711
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Clin Infect Dis. 2021 Nov 2;73(9):e2952-e2959
pubmed: 33098412
Kidney Med. 2021 Mar-Apr;3(2):309-311
pubmed: 33521620
Am J Kidney Dis. 2021 Feb;77(2):190-203.e1
pubmed: 32961244
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Clin J Am Soc Nephrol. 2021 Feb 8;16(2):290-292
pubmed: 33055191
Infect Dis Health. 2020 Aug;25(3):210-215
pubmed: 32473952
J Infect Dis. 2020 Sep 14;222(8):1265-1269
pubmed: 32726417
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
Endocrine. 2020 Dec;70(3):454-460
pubmed: 32870469
N Engl J Med. 2021 Feb 18;384(7):671-673
pubmed: 33503337
Open Forum Infect Dis. 2021 Jan 30;8(3):ofab048
pubmed: 33723510
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
mSphere. 2020 Nov 11;5(6):
pubmed: 33177214
Am J Kidney Dis. 2020 Sep;76(3):440-441
pubmed: 32512038
J Am Soc Nephrol. 2021 May 3;32(5):1033-1036
pubmed: 33637518
Clin Kidney J. 2020 Jun 22;13(3):334-339
pubmed: 32695323